MX338397B - Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. - Google Patents
Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.Info
- Publication number
- MX338397B MX338397B MX2013014465A MX2013014465A MX338397B MX 338397 B MX338397 B MX 338397B MX 2013014465 A MX2013014465 A MX 2013014465A MX 2013014465 A MX2013014465 A MX 2013014465A MX 338397 B MX338397 B MX 338397B
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- cxcr5
- humanized anti
- cxcr5 antibodies
- antibodies
- Prior art date
Links
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 abstract 3
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Physiology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
Abstract
La presente invención se refiere a un método para preparar un anticuerpo humanizado o fragmento del mismo, que comprende: (a) identificar una región variable humana homologa a una región variable de un anticuerpo no humano; (b) construir un modelo de homología de la región variable del anticuerpo no humano usando la región variable humana identifica en la etapa (a) y realizar simulaciones de dinámica molecular para obtener la trayectoria dinámica molecular de la región variable del anticuerpo no humano; (c) analizar la trayectoria dinámica molecular de la región variable del anticuerpo no humano y determinar las puntuaciones de flexibilidad de aminoácidos para identificar aminoácidos en la región variable del anticuerpo no humano que son flexibles y aminoácidos que flanquean el residuo flexible; (d) construir modelos de homología de líneas germinales de anticuerpo humano y realizar simulaciones de dinámica molecular para obtener las trayectorias dinámicas moleculares de la región variable de las líneas germinales del anticuerpo humano; (e) analizar las trayectorias dinámicas moleculares de la región variable de las líneas germinales del anticuerpo humano y determinar las puntuaciones de flexibilidad de aminoácidos para identificar aminoácidos en la región variable de las líneas germinales del anticuerpo humano que son flexibles y aminoácidos que flanquean el residuo flexible; (f) identificar la región variable humana de las líneas germinales del anticuerpo humano que muestra la trayectoria dinámica molecular más similar a la trayectoria dinámica molecular de la región variable del anticuerpo no humano e identificar las mutaciones de humanización comparando las puntuaciones de flexibilidad de los aminoácidos más flexibles de las etapas (c ) y (e); (g) reemplazar los aminoácidos identificados de la etapa (c) con los aminoácidos identificados de la etapa (f) para producir una región variable humanizada; (h) confirmar que la región variable humanizada de la etapa (g) se parece a un anticuerpo humano comparando la trayectoria dinámica molecular de la región variable de las líneas germinales del anticuerpo humano; e (i) construir de manera recombinante una región variable humanizada al unir la región variable humanizada de la etapa (g) con una secuencia humana para producir un anticuerpo humanizado o fragmento del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96879207P | 2007-08-29 | 2007-08-29 | |
| PCT/US2008/074381 WO2009032661A1 (en) | 2007-08-29 | 2008-08-27 | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX338397B true MX338397B (es) | 2016-04-15 |
Family
ID=40429297
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001975A MX2010001975A (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013014467A MX346172B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013005976A MX338395B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013014466A MX338474B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013014465A MX338397B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001975A MX2010001975A (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013014467A MX346172B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013005976A MX338395B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013014466A MX338474B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
Country Status (44)
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120263733A1 (en) * | 2002-11-15 | 2012-10-18 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation |
| WO2008010101A2 (en) | 2006-07-18 | 2008-01-24 | Sanofi-Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| MX2010001975A (es) | 2007-08-29 | 2010-03-10 | Sanofi Aventis | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
| SG2013061528A (en) * | 2008-08-14 | 2015-03-30 | Merck Sharp & Dohme | Methods for purifying antibodies using protein a affinity chromatography |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| CN102811736B (zh) * | 2009-11-30 | 2016-01-20 | 生物测试股份公司 | 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体 |
| EP2402371A1 (en) | 2010-07-01 | 2012-01-04 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| EP2397495A1 (en) | 2010-06-21 | 2011-12-21 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| SG181707A1 (en) | 2009-12-18 | 2012-07-30 | Sanofi Sa | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
| EP2336188A1 (en) | 2009-12-18 | 2011-06-22 | Sanofi-Aventis | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
| WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
| TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JP2014505239A (ja) * | 2010-12-14 | 2014-02-27 | モアハウス スクール オブ メディスン | 癌の治療または検出のための抗cxcl13および抗cxcr5抗体の使用 |
| AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| RU2663141C2 (ru) | 2012-01-20 | 2018-08-01 | Джензим Корпорейшн | Анти-cxcr3 антитела |
| EP4527855A3 (en) | 2012-03-26 | 2025-06-11 | Sanofi | Stable igg4 based binding agent formulations |
| PT2830658T (pt) * | 2012-03-26 | 2018-12-28 | Sanofi Sa | Formulações de agente de ligação igg4 estável |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| KR102367723B1 (ko) | 2012-03-28 | 2022-02-28 | 사노피 | 브라디키닌 b1 수용체 리간드에 대한 항체 |
| WO2014003744A1 (en) * | 2012-06-27 | 2014-01-03 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl 10, anti-cxcl 11, anti-cxcl 13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder |
| CN104870013A (zh) * | 2012-06-27 | 2015-08-26 | 吉安特科技公司 | 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 |
| TWI664192B (zh) | 2012-11-20 | 2019-07-01 | 法商賽諾菲公司 | 抗ceacam5抗體及其用途 |
| US20150322152A1 (en) | 2012-11-30 | 2015-11-12 | Institut Pasteur | Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| JP6441232B2 (ja) | 2012-12-27 | 2018-12-19 | サノフイSanofi | 抗lamp1抗体および抗体薬物コンジュゲート、ならびにその使用 |
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| JO3580B1 (ar) * | 2013-03-15 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لكيموكين elr+ cxc شامل |
| WO2014177652A1 (en) * | 2013-05-02 | 2014-11-06 | Ares Trading S.A | Monoclonal antibody directed against cxcr5 |
| EP3995145B1 (en) * | 2013-06-24 | 2024-10-16 | NexImmune, Inc. | Compositions and methods for immunotherapy |
| TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途 |
| UA118267C2 (uk) | 2013-08-13 | 2018-12-26 | Санофі | Антитіло до інгібітора активатора плазміногену 1 (раі-1) та його застосування |
| KR102846903B1 (ko) * | 2014-03-21 | 2025-08-20 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| JP2017525710A (ja) | 2014-08-22 | 2017-09-07 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Cxcr5に結合する抗原結合タンパク質 |
| CN107427573B (zh) * | 2014-12-24 | 2022-12-27 | 耐克西缪恩有限公司 | 用于免疫疗法的纳米颗粒组合物和方法 |
| CN114230667A (zh) | 2015-01-23 | 2022-03-25 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
| WO2016207089A1 (de) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen |
| US10973923B2 (en) | 2015-06-23 | 2021-04-13 | Bayer Pharma Aktiengesellschaft | Site specific homogeneous with KSP inhibitors |
| AU2016349152A1 (en) | 2015-11-03 | 2018-06-14 | Merck Patent Gmbh | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof |
| CN110317264B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物 |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| KR20180123047A (ko) | 2016-03-24 | 2018-11-14 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| RU2769326C2 (ru) * | 2016-07-05 | 2022-03-30 | Санофи | Составы на основе антитела |
| TWI760345B (zh) | 2016-07-05 | 2022-04-11 | 法商賽諾菲公司 | 抗體調配物 |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白 |
| JP7144051B2 (ja) * | 2016-09-26 | 2022-09-29 | Mpo株式会社 | 卵子、受精卵又は胚の質改善剤 |
| WO2018114578A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
| CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CN110914298A (zh) | 2016-12-22 | 2020-03-24 | 赛诺菲 | 具有耗减活性的人源化cxcr3抗体及其使用方法 |
| WO2018119288A1 (en) | 2016-12-22 | 2018-06-28 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
| EP3354278A1 (en) | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| AU2018238540B2 (en) * | 2017-03-22 | 2025-02-27 | Sanofi | Treatment of lupus using humanized anti-CXCR5 antibodies |
| TWI808963B (zh) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | 使用人類化抗cxcr5抗體治療狼瘡 |
| CA3064443A1 (en) * | 2017-05-24 | 2018-11-29 | Development Center For Biotechnology | Humanized antibodies against globo h and uses thereof in cancer treatments |
| KR102611853B1 (ko) | 2017-06-30 | 2023-12-08 | 자임워크스 비씨 인코포레이티드 | 안정화된 키메라 fabs |
| KR102804751B1 (ko) * | 2017-08-23 | 2025-05-13 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포 |
| EP3717516A1 (en) * | 2017-12-01 | 2020-10-07 | Pfizer Inc | Anti-cxcr5 antibodies and compositions and uses thereof |
| US20200360531A1 (en) | 2018-01-31 | 2020-11-19 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| US12331114B2 (en) * | 2018-02-13 | 2025-06-17 | Indian Institute Of Technology Bombay | Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation |
| KR20250121150A (ko) * | 2018-03-26 | 2025-08-11 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| WO2019243159A1 (de) * | 2018-06-18 | 2019-12-26 | Bayer Aktiengesellschaft | Gegen cxcr5 gerichtete binder-wirkstoff-konjugate mit enzymatisch spaltbaren linkern und verbessertem wirkungsprofil |
| EP3753954A1 (en) | 2019-06-21 | 2020-12-23 | Université de Franche-Comté | Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| JP2023525423A (ja) | 2020-01-15 | 2023-06-16 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Prameに特異的に結合する抗原結合タンパク質 |
| MX2022010538A (es) | 2020-02-28 | 2022-09-21 | Genzyme Corp | Polipeptidos de union modificados para conjugacion optimizada con farmacos. |
| WO2023010483A1 (en) * | 2021-08-05 | 2023-02-09 | Hifibio (Hk) Limited | Anti-human cxcr5 antibody and uses thereof |
| CA3180872A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab |
| JP2023522392A (ja) | 2020-04-24 | 2023-05-30 | サノフイ | 抗ceacam5抗体コンジュゲートおよびフォルフィリを含有する抗腫瘍組み合わせ |
| MX2022013404A (es) | 2020-04-24 | 2022-11-14 | Sanofi Sa | Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5, trifluridina y tipirazilo. |
| IL297311A (en) | 2020-04-24 | 2022-12-01 | Sanofi Sa | Antitumor combinations containing conjugates of antibodies to ceacam5 and folfox |
| JP2023540732A (ja) | 2020-09-04 | 2023-09-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ceacam5抗体及びコンジュゲート並びにそれらの使用 |
| CN112521499B (zh) * | 2020-12-24 | 2022-10-25 | 四川大学 | 抗cxcl13抗体及其用途 |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| KR20230154981A (ko) * | 2021-03-09 | 2023-11-09 | 하이파이바이오 (에이치케이) 리미티드 | 항-인간 cxcr5 항체 및 이의 용도 |
| EP4337699A4 (en) * | 2021-05-12 | 2025-07-23 | Biolegend Inc | ANTI-CCR8 ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF, AND AGENTS AND COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME |
| CN113278072B (zh) * | 2021-05-25 | 2023-06-20 | 河南凯普瑞生物技术有限公司 | 一种抗体的制备方法 |
| IL311153A (en) * | 2021-09-30 | 2024-04-01 | Betta Pharmaceuticals Co Ltd | Bispecific antibody and its use |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023079057A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
| WO2023170239A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Methods and tools for conjugation to antibodies |
| WO2023172968A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
| EP4514390A1 (en) | 2022-04-28 | 2025-03-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2 |
| WO2024011077A2 (en) | 2022-07-04 | 2024-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Monoclonal antibodies directed to phosphorylated psd95 and uses thereof |
| KR20250154496A (ko) | 2023-03-01 | 2025-10-28 | 사노피 | Ceacam5를 발현하는 신경내분비암을 치료하기 위한 항-ceacam5 면역접합체의 용도 |
| EP4427763A1 (en) | 2023-03-06 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
| KR20250169564A (ko) | 2023-03-23 | 2025-12-03 | 사노피 | 암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정 |
| WO2024251733A1 (en) | 2023-06-05 | 2024-12-12 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| CN117004700A (zh) * | 2023-10-07 | 2023-11-07 | 北京爱博生生物技术有限公司 | 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒 |
| WO2025172525A1 (en) | 2024-02-15 | 2025-08-21 | Merck Patent Gmbh | Anti-gd2 antibodies and immunoconjugates for the treatment of gd2 positive cancer |
| WO2025210264A1 (en) | 2024-04-04 | 2025-10-09 | Merck Patent Gmbh | Antibody-drug-conjugates binding napi2b |
| WO2025242845A1 (en) | 2024-05-22 | 2025-11-27 | Merck Patent Gmbh | Colorectal cancer treatment |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Il‐2レセプター特異的キメラ抗体 |
| CA1341411C (en) | 1988-04-16 | 2002-12-17 | Lutz Riechmann | Method for producing fv fragments in eukaryotic cells |
| DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| JPH09506761A (ja) | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
| JPH06510524A (ja) | 1991-05-14 | 1994-11-24 | ユニバーシティ オブ コネチカット | 免疫原性タンパク質をコードする遺伝子の標的への配達 |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE69231385T2 (de) | 1991-06-05 | 2001-04-12 | The Board Of Regents Acting For And On Behalf Of The Unversity Of Michigan, Ann Arbor | Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren |
| JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| CA2133411A1 (en) | 1992-04-03 | 1993-10-14 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
| WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| PT671923E (pt) | 1992-10-09 | 2001-10-30 | Advanced Tissue Sciences Inc | Celulas de reserva do figado |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0850313B8 (en) | 1995-09-08 | 2009-07-29 | Genzyme Corporation | Improved aav vectors for gene therapy |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| PT970126E (pt) | 1997-04-14 | 2001-10-30 | Micromet Ag | Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
| WO1999023105A1 (en) | 1997-11-03 | 1999-05-14 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
| WO2000052054A2 (en) | 1999-03-01 | 2000-09-08 | Genentech, Inc. | Antibodies for cancer therapy and diagnosis |
| WO2001077137A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| WO2002020615A2 (en) * | 2000-09-08 | 2002-03-14 | Micromet Ag | Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| AU2002357379A1 (en) * | 2001-12-21 | 2003-07-15 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US20050276812A1 (en) * | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| AU2003239248A1 (en) * | 2002-06-07 | 2003-12-22 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And | Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
| WO2004015426A1 (en) * | 2002-08-06 | 2004-02-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) |
| TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US20060148009A1 (en) | 2004-10-12 | 2006-07-06 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
| TW200813086A (en) | 2006-05-11 | 2008-03-16 | Hoffmann La Roche | Immunereconstituted mouse |
| MX2010001975A (es) | 2007-08-29 | 2010-03-10 | Sanofi Aventis | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
-
2008
- 2008-08-27 MX MX2010001975A patent/MX2010001975A/es active IP Right Grant
- 2008-08-27 HU HUE08798744A patent/HUE037489T2/hu unknown
- 2008-08-27 NO NO08798744A patent/NO2195023T3/no unknown
- 2008-08-27 PA PA20088794201A patent/PA8794201A1/es unknown
- 2008-08-27 RU RU2010111751/10A patent/RU2571515C2/ru not_active IP Right Cessation
- 2008-08-27 MX MX2013014467A patent/MX346172B/es unknown
- 2008-08-27 UA UAA201312423A patent/UA117446C2/uk unknown
- 2008-08-27 DK DK08798744.2T patent/DK2195023T3/en active
- 2008-08-27 SG SG10201407388XA patent/SG10201407388XA/en unknown
- 2008-08-27 KR KR1020157017528A patent/KR101701140B1/ko not_active Expired - Fee Related
- 2008-08-27 HR HRP20180873TT patent/HRP20180873T1/hr unknown
- 2008-08-27 MY MYPI2010000837A patent/MY159201A/en unknown
- 2008-08-27 JP JP2010523100A patent/JP5743543B2/ja active Active
- 2008-08-27 WO PCT/US2008/074381 patent/WO2009032661A1/en not_active Ceased
- 2008-08-27 NZ NZ583605A patent/NZ583605A/xx not_active IP Right Cessation
- 2008-08-27 RS RS20180659A patent/RS57273B1/sr unknown
- 2008-08-27 PL PL08798744T patent/PL2195023T3/pl unknown
- 2008-08-27 EP EP20191628.5A patent/EP3792284A1/en active Pending
- 2008-08-27 ES ES08798744.2T patent/ES2672769T3/es active Active
- 2008-08-27 MX MX2013005976A patent/MX338395B/es unknown
- 2008-08-27 CN CN201410307133.3A patent/CN104017078B/zh active Active
- 2008-08-27 PT PT87987442T patent/PT2195023T/pt unknown
- 2008-08-27 CN CN201410307453.9A patent/CN104017079B/zh active Active
- 2008-08-27 MX MX2013014466A patent/MX338474B/es unknown
- 2008-08-27 BR BRPI0815983A patent/BRPI0815983A2/pt not_active Application Discontinuation
- 2008-08-27 CA CA2698203A patent/CA2698203C/en active Active
- 2008-08-27 TR TR2018/07983T patent/TR201807983T4/tr unknown
- 2008-08-27 EP EP08798744.2A patent/EP2195023B1/en active Active
- 2008-08-27 AU AU2008296538A patent/AU2008296538B2/en active Active
- 2008-08-27 PE PE2008001444A patent/PE20090993A1/es not_active Application Discontinuation
- 2008-08-27 KR KR1020147023916A patent/KR20140117638A/ko not_active Ceased
- 2008-08-27 EP EP18154804.1A patent/EP3354662B1/en active Active
- 2008-08-27 RU RU2015147300A patent/RU2015147300A/ru not_active Application Discontinuation
- 2008-08-27 UA UAA201003491A patent/UA104715C2/uk unknown
- 2008-08-27 US US12/675,799 patent/US8647622B2/en active Active
- 2008-08-27 CN CN200880113572.3A patent/CN101842115B/zh active Active
- 2008-08-27 KR KR1020147026311A patent/KR101667944B1/ko not_active Expired - Fee Related
- 2008-08-27 CN CN202010815880.3A patent/CN111909273B/zh active Active
- 2008-08-27 MX MX2013014465A patent/MX338397B/es unknown
- 2008-08-27 LT LTEP08798744.2T patent/LT2195023T/lt unknown
- 2008-08-27 KR KR1020107006630A patent/KR101599704B1/ko not_active Expired - Fee Related
- 2008-08-27 SI SI200831964T patent/SI2195023T1/en unknown
- 2008-08-27 UY UY31309A patent/UY31309A1/es not_active Application Discontinuation
- 2008-08-29 TW TW105114943A patent/TWI608017B/zh not_active IP Right Cessation
- 2008-08-29 CL CL2008002565A patent/CL2008002565A1/es unknown
- 2008-08-29 TW TW103111438A patent/TWI574976B/zh not_active IP Right Cessation
- 2008-08-29 TW TW097133372A patent/TWI439468B/zh not_active IP Right Cessation
- 2008-08-29 AR ARP080103776A patent/AR068354A1/es not_active Application Discontinuation
- 2008-08-29 TW TW106127131A patent/TW201741341A/zh unknown
-
2010
- 2010-02-19 NI NI201000028A patent/NI201000028A/es unknown
- 2010-02-19 NI NI2010000281A patent/NI201000281A/es unknown
- 2010-02-23 EC EC2010009985A patent/ECSP109985A/es unknown
- 2010-02-23 TN TNP2010000092A patent/TN2010000092A1/fr unknown
- 2010-02-23 CR CR11293A patent/CR11293A/es unknown
- 2010-02-24 SV SV2010003494A patent/SV2010003494A/es unknown
- 2010-02-25 IL IL204173A patent/IL204173A/en active IP Right Grant
- 2010-02-26 DO DO2010000069A patent/DOP2010000069A/es unknown
- 2010-03-02 ZA ZA2010/01514A patent/ZA201001514B/en unknown
- 2010-03-08 MA MA32673A patent/MA31821B1/fr unknown
- 2010-04-05 CO CO10037770A patent/CO6270238A2/es active IP Right Grant
-
2013
- 2013-03-11 US US13/794,253 patent/US20130243793A1/en not_active Abandoned
- 2013-03-11 US US13/794,224 patent/US9228019B2/en active Active
- 2013-03-11 US US13/794,264 patent/US8980262B2/en active Active
- 2013-03-11 US US13/794,281 patent/US9175087B2/en active Active
- 2013-03-11 US US13/794,244 patent/US9243067B2/en active Active
-
2014
- 2014-12-26 JP JP2014263780A patent/JP6129152B2/ja active Active
-
2015
- 2015-02-05 PH PH12015500248A patent/PH12015500248A1/en unknown
- 2015-02-05 CR CR20150054A patent/CR20150054A/es unknown
- 2015-04-28 IL IL238505A patent/IL238505A/en active IP Right Grant
-
2016
- 2016-08-22 US US15/243,046 patent/US9815902B2/en active Active
-
2017
- 2017-03-06 JP JP2017041210A patent/JP2017123866A/ja active Pending
-
2018
- 2018-01-03 US US15/725,253 patent/US20180100019A1/en not_active Abandoned
- 2018-06-06 CY CY181100591T patent/CY1120665T1/el unknown
- 2018-07-20 AR ARP180102046 patent/AR112564A2/es unknown
-
2021
- 2021-08-20 US US17/407,651 patent/US20220073629A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| AU2016219704A1 (en) | Anti-Notch1 antibodies | |
| MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
| MY177564A (en) | Anti-nr10 antibody and use thereof | |
| MY155621A (en) | Axl antibodies | |
| MX2009013082A (es) | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. | |
| UA100874C2 (en) | Bivalent bispecific antibodies | |
| MX2010006396A (es) | Anticuerpos bivalentes, biespecificos. | |
| MX2010005888A (es) | Anticuerpos bivalentes biespecificos. | |
| MX2010005682A (es) | Anticuerpos bivalentes, biespecificos. | |
| MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
| WO2010032059A3 (en) | Antibodies directed to cd105 and uses thereof | |
| PH12013500564A1 (en) | Anti-cd48 antibodies and uses thereof | |
| PH12013500356A1 (en) | Engineered anti-tslp antibody | |
| MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
| UA113397C2 (xx) | Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3 | |
| MX2009006891A (es) | Anticuerpos cd44. | |
| MY151191A (en) | Novel antibodies | |
| WO2012149478A3 (en) | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| WO2008097439A3 (en) | Anti-autoimmune antibodies for treatment of pemphigus | |
| EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
| MY154715A (en) | Anti-nr10 antibody and use thereof | |
| MY149492A (en) | Immunoglobulins directed against nogo |